Sponsored Content

KESIMPTA® (ofatumumab): Flexibility of a Self-Administered RMS Therapy

 Content Sponsored by Novartis Pharmaceuticals Corporation Hear Dr David Hojnacki discuss how the flexibility of KESIMPTA, an at-home, self-administered DMT could fit for your patients. Please click here for full Prescribing Information, including Medication Guide. Please see below for full Important Safety Information. INDICATION AND IMPORTANT SAFETY INFORMATION INDICATIONKESIMPTA is indicated for the treatment of relapsing forms of…

Targeted and Precisely Delivered Therapy: Understanding KESIMPTA® (ofatumumab) Mechanism of Action

 Content Sponsored by Novartis Pharmaceuticals Corporation Dr Ravi Dukkipati weighs in on the role of B cells in RMS pathogenesis and discusses the MOA of KESIMPTA, a targeted and precisely delivered B-cell therapy for RMS. Please click here for full Prescribing Information, including Medication Guide. Please see below for full Important Safety Information. INDICATION AND IMPORTANT SAFETY INFORMATION…

A Letter to My Younger Self

Content Sponsored by Eisai Inc. “Letters to My Younger Self’ are written by epilepsy patients and caregivers, highlighting what they wished they had known at the onset of their journey toward seizure freedom. In the letter below, Dr.  John B. Ingram, pediatric epileptologist at the University of Mississippi Medical Center, shares his own experiences as a…

Next post in Industry Supported Education